What is the amount of ICUs across the world where the trial was conducted.
100
18
What is age a patient must be to included in the study?
100
> 18 years of age
What is the minimum requirement of age to be included in the study?
100
Angiotensin II can raise BP in patients with severe vasodilatory shock already on a high dose of background vasopressors.
What is the hypothesis used to delineate that safety and vasopressor potency of angiotensin II.
100
This was the dose that was used upon initiation of study infusion.
What is 20 ng/kg/min?
200
May, 2015 - January, 2017
-What is the time span ATHOS-3 was conducted?
200
A total sum catecholamine dose of >0.2ug/kg/min for a minimum of 6 hours and a maximum of 48 hours to maintain MAP between 55-75mmHg
What is the definition of catecholamine-resistance hypotension?
200
MELD of >30
What is the liver failure score considered too high to be enrolled in the ATHOS-3 study?
200
The practice allows clinicians to use their clinical judgement regarding how to best leverage three different drugs to manage hypotension.
What is considered "real world" practice?
200
This is how a patient was described if he or she required an increase in the background standard-of care vasopressors.
What is a non-responder?
300
9
What is the amount of countries the study was conducted?
300
indwelling urinary catheter
What is expected to be present and remain in place for at least the initial 48 hours of study?
300
< 12 hours
What is the expected lifespan that could not be included in the study?
300
A new vasopressor is introduced, the clinical MAP target is maintained and catecholamines are titrated down to estimate the effect on BP.
What is the second phase of the ATHOS-3 trial?
300
This is the maximum rate of administration of the study medication or placebo allowed ruing the first 3 hours of the study.
What is 200 ng/kg/min?
400
North America, Australasia and Europe
What are the 3 continents the study was conducted?
400
ScvO2 > 70% and CVP > 8 mmHg or C.I. >2.3L/min/m2
What is the criteria of high-output shock?
400
>20% TBSA
What is the amount of burns covering the body considered to be too high to be included in the ATHOS-3 trial?
400
An increase of MAP at hour 3 of at least 10 mmHg from baseline or an increase to a MAP of at least 75 mmHg, without an increase in the dose of background vasopressors.
What is the primary endpoint of the ATHOS-3 trial?
500
321
What is the total amount of patients who underwent study regimen initiation?
500
25 ml/kg of crystalloid or colloid equivalent over the previous 24-hr. period.
What is considered to be adequate volume resuscitation?
500
> 500 mg daily
What is the maximum daily dose of hydrocortisone that was considered to be too high to be enrolled in the ATHOS-3 study?
500
Changes in the CV SOFA score and the total SOFA score between baseline measurement and hours 48.
What are the secondary efficacy end points that were measured in the ATHOS-3 trial?
500
This is the hour duration the study infusion was discontinued according to a protocol-specified tapering process.